How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

1,855 results for

Imiquimod

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1761. Postsurgical use of imiquimod 5% cream in the prevention of earlobe keloid recurrences: results of an open-label, pilot study. (Abstract)

Postsurgical use of imiquimod 5% cream in the prevention of earlobe keloid recurrences: results of an open-label, pilot study. Traditional surgical modalities for the management of earlobe keloids are often associated with high recurrence rates. A recent report suggests that imiquimod 5% cream can be effective in the prevention of keloid recurrences after surgical excision.To establish the safety and efficacy of imiquimod 5% cream in the prevention of recurrences of excised earlobe (...) keloids.Patients who attended a dermatologic surgery clinic for the treatment of earlobe keloids were recruited into the study. Earlobe keloids underwent parallel shave excision. Imiquimod 5% cream was applied daily for 8 weeks followed by an observation period of 16 weeks. In patients who presented with bilateral earlobe keloids, paired comparisons of imiquimod versus intralesional steroid injections were performed.Eight earlobes were treated with imiquimod 5% cream after parallel keloid removal. Twenty-four

2005 Dermatologic Surgery

1762. Infiltrative trichilemmal carcinoma treated with 5% imiquimod cream. (Abstract)

Infiltrative trichilemmal carcinoma treated with 5% imiquimod cream. Trichilemmal carcinoma (TLC) is a rare cutaneous neoplasm that occurs in the sun-exposed skin of the elderly. Although the clinical behavior of TLC appears to be relatively indolent, wide excision or Mohs micrographic surgery is the recommended treatment owing to its locally aggressive growth. Recently, imiquimod has become an important part of the armamentarium in the treatment of nonmelanoma skin cancer.This article serves (...) to remind dermatologists that in addition to Mohs micrographic surgery and surgical excision, imiquimod 5% cream may have a role in the treatment of TLC.In addition to a review of the literature, we present a case of TLC successfully treated with 5% imiquimod cream.Its nonsurgical approach and excellent cosmetic result make imiquimod 5% cream another promising therapeutic option for TLC, even though it is histologically infiltrative.

2005 Dermatologic Surgery

1763. Topical imiquimod treatment for nodular basal cell carcinomas: an open-label series. (Abstract)

Topical imiquimod treatment for nodular basal cell carcinomas: an open-label series. Imiquimod has been used for basal cell carcinomas (BCCs). This is the first open-label series using imiquimod for nodular BCC with Mohs surgery resection for confirmation of treatment.To evaluate the efficacy of topical imiquimod in patients with biopsy-proven nodular BCC.After 12 weeks for three times a week application, treatment sites at week 15 were surgically excised using Mohs micrographic surgery. All 15

2004 Dermatologic Surgery

1764. First case series on the use of imiquimod for morphoea. (Abstract)

First case series on the use of imiquimod for morphoea. Morphoea is characterized by fibrosis, which is mediated by cytokines including transforming growth factor (TGF)-beta.Our objective was to use imiquimod 5% cream (Aldara), an inducer of interferon-gamma, known to inhibit TGF-beta, to treat morphoea.Patients with morphoea were treated with imiquimod and evaluated during their follow-up visits to 6 months.The dyspigmentation, induration and erythema of 12 patients with morphoea lesions (...) improved. The histology of the skin also showed a decrease in dermal thickness.This is the first case series describing the successful application of imiquimod in the management of morphoea.

2005 British Journal of Dermatology

1765. Use of 5% imiquimod cream in the treatment of facial basal cell carcinoma: a 3-year retrospective follow-up study. Full Text available with Trip Pro

Use of 5% imiquimod cream in the treatment of facial basal cell carcinoma: a 3-year retrospective follow-up study. There has been considerable research into the safety and efficacy of topical 5% imiquimod cream for the treatment of skin cancers in recent years, in particular superficial and nodular basal cell carcinomas. However, there are limited long-term follow-up studies. This retrospective study aims to determine the efficacy of 5% imiquimod cream in the treatment of facial basal cell (...) carcinomas over 3 years. Medical records of 12 patients treated with 5% imiquimod cream at a private dermatology practice during 2001 and 2002 were retrospectively reviewed. Target tumours included superficial and nodular basal cell carcinomas, giving a total lesion number of 19. Patients were commenced on a once daily treatment regimen for up to 9 weeks, and given rest periods as required according to the severity of application site reactions. We found that 5% imiquimod cream is an effective treatment

2006 Australasian Journal of Dermatology

1766. An open-label, pilot study examining the efficacy of curettage followed by imiquimod 5% cream for the treatment of primary nodular basal cell carcinoma. (Abstract)

An open-label, pilot study examining the efficacy of curettage followed by imiquimod 5% cream for the treatment of primary nodular basal cell carcinoma. SUMMARY The short-term efficacy of imiquimod 5% cream for the treatment of primary superficial basal cell carcinoma has been established. This study investigated its efficacy following curettage (without electrodesiccation) for the treatment of primary nodular basal cell carcinoma on the trunk and limbs. Seventeen patients with a total of 34 (...) lesions were enrolled. Curettage was used to de-bulk the lesion and confirm suitable histology. Lesions displaying more aggressive subtypes (such as micronodular or morpheoic components) were excluded. Lesions were treated daily for 6 to 10 weeks with imiquimod 5% cream. Three months post treatment all lesions were excised, and 32 of 34 treated lesions (94%) were histologically clear of basal cell carcinoma. Fourteen of 17 patients rated the cosmetic outcome of treatment as excellent or good

2006 Australasian Journal of Dermatology

1767. Invasive squamous cell carcinoma after treatment of carcinoma in situ with 5% imiquimod cream. (Abstract)

Invasive squamous cell carcinoma after treatment of carcinoma in situ with 5% imiquimod cream. Squamous cell carcinoma in situ has the potential to progress to invasive squamous cell carcinoma. This report presents two cases of punch biopsy-proven squamous cell carcinoma in situ, treated with once-daily application of 5% imiquimod cream for 6 weeks. Both patients developed moderate local inflammatory reactions during treatment. The first patient demonstrated clinical clearance of the scalp (...) lesion after treatment. Two months later, he re-presented with a subcutaneous nodule at the same site. Histology was consistent with recurrent squamous cell carcinoma. Five months following excision of the recurrent tumour, he presented with metastatic squamous cell carcinoma to a cervical lymph node. The second patient had low-grade chronic lymphocytic leukaemia and presented with squamous cell carcinoma in situ of the leg that failed to clear clinically after treatment with imiquimod. He presented

2006 Australasian Journal of Dermatology

1768. Two-year interim results from a 5-year study evaluating clinical recurrence of superficial basal cell carcinoma after treatment with imiquimod 5% cream daily for 6 weeks. (Abstract)

Two-year interim results from a 5-year study evaluating clinical recurrence of superficial basal cell carcinoma after treatment with imiquimod 5% cream daily for 6 weeks. Imiquimod 5% cream is approved in the USA, Europe and Australia to treat superficial basal cell carcinoma, using a regimen of once daily, 5 times per week for 6 weeks. Vehicle-controlled, phase III clinical trials show that imiquimod is safe and effective for treating superficial basal cell carcinoma with dosing 5 or 7 times (...) were evaluated for recurrence at the 3-, 6-, 12- and 24-month follow-up visits. The initial clearance rate at 12 weeks post treatment was 94.1%. The proportion of subjects who were clinically clear at the 2-year follow-up visit was estimated to be 82.0%. Imiquimod was tolerated when applied daily, with erythema reported for all subjects participating in the study. The recurrence rate observed suggests that once daily dosing and 5x/week dosing yield similar clearance rates, but daily dosing

2006 Australasian Journal of Dermatology

1769. Successful treatment of multiple actinic keratoses in organ transplant patients with topical 5% imiquimod: a report of six cases. (Abstract)

Successful treatment of multiple actinic keratoses in organ transplant patients with topical 5% imiquimod: a report of six cases. Nonmelanoma skin cancer represents a significant cause of morbidity in organ transplant recipients (OTRs). Cutaneous malignancies, mainly invasive squamous cell carcinoma and its precursor actinic keratosis (AK), appear approximately 5-10 years after organ transplantation. Impaired wound healing and high recurrence rates in immunocompromised patients treated (...) with destructive therapies such as cryosurgery or topical 5-fluorouracil represent frequently known complications.To evaluate the safety and efficacy of imiqimod 5% in the treatment of AKs in OTRs.Six OTRs (two kidney, two heart, one lung and one liver) with extensive AKs were treated with imiquimod 5% cream two to three times weekly in an open-label uncontrolled, nonrandomized pilot study.In five of six patients treated with imiquimod 5% cream all AK lesions were cleared after 12-16 weeks. One patient showed

2006 British Journal of Dermatology

1770. Effectiveness of imiquimod 5% cream for treatment of extensive anogenital warts in a seven-year-old child. (Abstract)

Effectiveness of imiquimod 5% cream for treatment of extensive anogenital warts in a seven-year-old child. Conventional treatment options for anogenital warts in prepubertal children rely on chemical and physical destruction methods that can be difficult and painful and frequently require the use of general anesthesia. Other approaches include the use of immunotherapies, as topical imiquimod and intralesional or systemic interferon. We report a 7-year-old girl with extensive anogenital warts (...) who was successfully treated with topical 5% imiquimod cream.

2007 Pediatric Infectious Dsease Journal

1771. Increased frequency of dosing of imiquimod 5% cream in the treatment of external genital warts in women. (Abstract)

Increased frequency of dosing of imiquimod 5% cream in the treatment of external genital warts in women. 11818121 2002 04 09 2018 11 30 0020-7292 76 2 2002 Feb International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics Int J Gynaecol Obstet Increased frequency of dosing of imiquimod 5% cream in the treatment of external genital warts in women. 191-3 Trofatter K F KF Jr Department of Obstetrics and Gynecology (...) , The University of Tennessee Medical Center at Knoxville, Knoxville, TN, USA. kftrofatter@netscape.net Ferenczy A A Fife K H KH eng Clinical Trial Clinical Trial, Phase II Journal Article Randomized Controlled Trial Research Support, Non-U.S. Gov't United States Int J Gynaecol Obstet 0210174 0020-7292 0 Adjuvants, Immunologic 0 Aminoquinolines P1QW714R7M Imiquimod IM Adjuvants, Immunologic administration & dosage Adult Aminoquinolines administration & dosage Condylomata Acuminata drug therapy Drug

2002 International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics Controlled trial quality: uncertain

1772. Effect of imiquimod on cytokine induction in first trimester trophoblasts. Full Text available with Trip Pro

Effect of imiquimod on cytokine induction in first trimester trophoblasts. Imiquimod (IQ) is used clinically for the topical treatment of external genital warts. IQ is an immune response modifier and induces the expression of interferon-alpha and other cytokines in human Peripheral Blood Monocytes (PBMC). Trophoblasts have been previously shown to express inflammatory cytokines upon lipopolysaccharide (LPS) stimulation. The objective of this study was to evaluate the ability of IQ to induce

2000 Infectious diseases in obstetrics and gynecology

1773. Imiquimod in Preventing Cervical Cancer in Women With Cervical Neoplasia

Imiquimod in Preventing Cervical Cancer in Women With Cervical Neoplasia Imiquimod in Preventing Cervical Cancer in Women With Cervical Neoplasia - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Imiquimod (...) (NCI) Information provided by (Responsible Party): Alliance for Clinical Trials in Oncology Study Details Study Description Go to Brief Summary: RATIONALE: Chemoprevention therapy is the use of certain substances to try to prevent the development of cancer. Applying topical imiquimod before abnormal cervical cells are removed may be effective in preventing cervical cancer. PURPOSE: Randomized phase II trial to study the effectiveness of applying topical imiquimod before abnormal cervical cells

2002 Clinical Trials

1774. Topical Imiquimod Compared With Surgery in Treating Patients With Basal Cell Skin Cancer

Topical Imiquimod Compared With Surgery in Treating Patients With Basal Cell Skin Cancer Topical Imiquimod Compared With Surgery in Treating Patients With Basal Cell Skin Cancer - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies (...) before adding more. Topical Imiquimod Compared With Surgery in Treating Patients With Basal Cell Skin Cancer The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT00066872 Recruitment Status : Completed First Posted : August 7, 2003 Last Update Posted : September 17, 2013 Sponsor: Queen's Medical Centre

2003 Clinical Trials

1775. Immune response modification: imiquimod. (Abstract)

Immune response modification: imiquimod. Imiquimod is 1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine and has a molecular formula of C14H16N4. It was discovered by researchers at 3M Pharmaceuticals (St Paul, MN, USA) and is the newest in a class of drugs known as immune response modifiers. Imiquimod 5% cream has been formulated for the treatment of external genital and perianal warts (condylomata acuminata) in male and female patients. Each gram of 5% cream contains 50 mg of imiquimod (...) . In preclinical studies, imiquimod induced the production of cytokines, the principal one for antiviral activity being interferon-alpha. Imiquimod does not induce direct antiviral activity, nor does it cause direct, non-specific cytolytic destruction. Preclinical studies suggest that its antiviral action results from in vivo cytokine-induced activation of the immune system. A double-blind, placebo-controlled study designed to evaluate this hypothesis has been previously presented. The results of the study

1998 The Australasian journal of dermatology

1776. Imiquimod in clinical practice. (Abstract)

Imiquimod in clinical practice. Applied topically, imiquimod induces the production of interferon-alpha plus other cytokines. Because intralesional interferon is effective in the treatment of condylomata acuminata (genital warts), topical imiquimod has also been investigated as a potential therapy for this condition. The dosing regimen found to best balance efficacy, side-effects and practicality is 5% imiquimod cream applied overnight by the patient three times weekly until warts clear, for up (...) to 16 weeks. The largest double-blind trial to examine this protocol involved 311 patients with external anogenital warts who were randomized to use imiquimod 5% cream, imiquimod 1% cream or vehicle cream. Evaluation of all patients given medication at any time showed that 50% of those who received 5% imiquimod experienced clearing of all baseline warts, as compared to 21% of those who used 1% imiquimod and 11% of those treated with vehicle. Overall, 5% imiquimod treatment was significantly more

1998 The Australasian journal of dermatology

1777. Self-administered topical 5% imiquimod cream for external anogenital warts. HPV Study Group. Human PapillomaVirus. (Abstract)

Self-administered topical 5% imiquimod cream for external anogenital warts. HPV Study Group. Human PapillomaVirus. To compare the safety and effectiveness of 5% and 1% imiquimod cream with vehicle cream in the treatment of external anogenital warts.Randomized, double-blind, placebo-controlled comparison that evaluated patients for total clearance of their warts. Patients who experienced total clearance were evaluated for recurrence in a 12-week follow-up.Eleven ambulatory offices, including (...) both private physician offices and referral medical centers.Three hundred eleven healthy men and women aged 18 years or older with 2 to 50 external anogenital warts were recruited from the practices of investigators, referring physicians, and advertisements. Eighty-two additional patients were screened but did not qualify. Four patients discontinued use of the medication because of adverse effects.Five percent imiquimod (Aldara) cream, 1% imiquimod cream, or vehicle cream was applied to all

1998 Archives of Dermatology Controlled trial quality: predicted high

1778. Treatment of genital warts with an immune-response modifier (imiquimod). (Abstract)

Treatment of genital warts with an immune-response modifier (imiquimod). Genital warts are a common sexually transmitted disease caused by human papillomavirus. Imiquimod is a novel immune-response modifier capable of inducing a variety of cytokines, including interferon alfa, tumor necrosis factor-alpha, as well as interleukins 1, 6, and 8. In animal models imiquimod has demonstrated antiviral, antitumor, and adjuvant activity. In vitro, imiquimod has no antiviral or antitumor activity.Our (...) purpose was to determine the safety and efficacy of topical imiquimod for the treatment of external genital warts.This prospective double-blind, placebo-controlled, parallel design clinical trial was performed in three outpatient centers, a public health clinic, a university-based clinic, and a private practice. One hundred eight patients with external genital warts (predominantly white men) were entered into the trial. Fifty-one patients were randomly selected to receive 5% imiquimod cream; 57

1998 Journal of the American Academy of Dermatology Controlled trial quality: predicted high

1779. A randomized, controlled, molecular study of condylomata acuminata clearance during treatment with imiquimod. (Abstract)

A randomized, controlled, molecular study of condylomata acuminata clearance during treatment with imiquimod. Imiquimod, an immune response modifier, has been demonstrated to be safe and effective in the treatment of external genital and perianal warts caused by human papillomavirus (HPV). To identify the molecular mechanism(s) by which condylomata acuminata clear during topical treatment with imiquimod, wart skin biopsies were taken from patients before treatment, at treatment week 6 (...) , and at the end of treatment. Tissues were analyzed for HPV DNA and for mRNA of several cytokines and HPV gene products. Wart clearance was associated with evidence of tissue production of interferon-alpha, -beta, and -gamma and tumor necrosis factor-alpha. Regression of warts was strongly associated with a decrease in HPV DNA and in mRNA expression for both early and late viral proteins. Thus, topical imiquimod treatment of anogenital warts led to significant increases in local production of multiple

1998 The Journal of infectious diseases Controlled trial quality: uncertain

1780. Management of female genital warts with an analog of imiquimod 2% in cream: a randomized, double-blind, placebo-controlled study. (Abstract)

Management of female genital warts with an analog of imiquimod 2% in cream: a randomized, double-blind, placebo-controlled study. The purpose of this randomized, double-blind, placebo-controlled study was to determine the clinical efficacy and tolerability of an analog of imiquimod (2%)in cream to cure genital warts in women. Sixty preselected women, ranging between 18 and 45 years of age (mean 24.3) and having 411 lesions (mean 6.8) with clinical, histopathological and polymerase chain (...) % of patients and 42.8% of warts were cured. Code disclosure revealed that imiquimod cream had cured 83.3% of the treated patients and 84.3% of the tested warts, while the placebo healed one subject and four warts (p < 0.0001). Eight patients (13.3%) in the imiquimod group experienced mild to moderate, non-objective, drug-induced symptoms with no dropouts. Among the 26 cured patients, five had a relapse after 11 months. In conclusion, the data presented demonstrate that 2% imiquimod in cream with mild

1998 The Journal of dermatology Controlled trial quality: uncertain

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>